be used in disease with multifocal pathology. However, this paper highlights reasonable outcomes from focal therapy. The most important factor when dealing with salvage therapy for the prostate, is to diagnose the patient quickly and then treat the patient with the most appropriate modality for them. In certain cases, this would mean focal therapy. An argument has even been made for focal therapy in the case of radiorecurrent prostate cancer [4] in the past. This is still under debate.
Despite good diagnostics, many in this group of patients often present with metastatic disease [3] . By definition recurrent prostate cancer is more aggressive disease. Simone Albisinni examined PSMA PET-directed radiotherapy for oligometastatic disease after prostatectomy, this is a possible treatment option that could be used, in the frailer patient group. This is clearly important as it allows for a targeted therapy in the case of metastatic disease [2, 6] . Alternatively, for patients fit for surgery Steven Joniau examined metastectomy for visceral and skeletal oligorecurrent prostate cancer. This again highlights how far prostate cancer treatment has developed-to considering metastectomy in fit patients.
We 
